KRAS: A promising therapeutic target for cancer treatment.

KRAS: A promising therapeutic target for cancer treatment.
Curr Top Med Chem. 2019 Sep 05;:
Authors: Wu HZ, Xiao JQ, Xiao SS, Cheng Y
Abstract
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. Scientists have not successfully developed drugs that target KRAS, although efforts have been made last three decades. In this review, we highlight the emerging experimental strategies of impairing KRAS membrane localization and the direct targeting of KRAS. We also conclude the combinatorial therapies and RNA interference technology for treatment of KRAS mutant cancers. Moreover, the virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
PMID: 31486755 [PubMed - as supplied by publisher]

Source: Current Topics in Medicinal Chemistry - September 4, 2019 Category: Chemistry Authors: Wu HZ, Xiao JQ, Xiao SS, Cheng Y Tags: Curr Top Med Chem Source Type: research